1. A phase II single-center study of the tolerability and efficacy of TBX-3400 in subjects with chronic HBV or hepatitis virus associated liver tumors resistant or refractory to standard therapies. (Principle Investigator)
2. Development of patient – derived organoids with accompanying molecular and anti- cancer drug response data for precision oncology. (Co-Investigator)
3. Development of AI-assisted software for holistic need assessment in cancer patients to promote individualized cancer care. (Principle Investigator)
4. Identification of Immunogenic Personal Tumor-Specific Mutations and Neoantigens from Solid tumor or Liquid biopsy (Principle investigator)
5. Personalized neoantigen peptide vaccine for cancer treatment (Principle investigator)

Journal Affiliations